




RealRate

PHARMACEUTICAL 2018

Chinook Therapeutics INC
Rank 177 of 332



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Chinook Therapeutics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Chinook Therapeutics INC compared to the market average is the variable Assets, increasing the Economic Capital Ratio by 45% points. The greatest weakness of Chinook Therapeutics INC is the variable Other Liabilities, reducing the Economic Capital Ratio by 92% points.

The company's Economic Capital Ratio, given in the ranking table, is 254%, being 2.2% points above the market average of 252%.

Input Variable	Value in 1000 USD
Assets, Current	350,131
Cost of Goods Sold	0
Intangible Assets	39,830
Liabilities, Current	41,401
Liabilities, Non-Current	818
Other Assets	24,082
Other Compr. Net Income	3,577
Other Expenses	-10,805
Other Liabilities	165,436
Other Net Income	3,226
Other Revenues	17,239
Property and Equipment	31,085
Research and Development	89,382
Selling, General and Administrative Expense	33,751

Output Variable	Value in 1000 USD
Assets	445,128
Liabilities	207,655
Expenses	112,328
Revenues	17,239
Stockholders Equity	237,473
Net Income	-91,863
Comprehensive Net Income	-90,074
BaseVar	394,576
ECR before LimitedLiability	131%
Economic Capital Ratio	254%